News and Milestones

26 August 2022

AC BioScience closes fourth Seed Round for CHF 2.5 million

28 March 2022

AC BioScience has been awarded Gold status by the EIT Health Investor Network

3 March 2022

Publication of an article in Cancers entitled "Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?"

3 February 2022

AC BioScience obtains Eurostars grant to accelerate the preclinical development of its immuno-stimulatory lead molecule ACB1801.

1 February 2022

Peter Hug, Ph.D., appointed to the Board of Directors

12 October 2021

AC BioScience obtains convertible loan of CHF 1.3 million.

1 September 2021

Jean-François Dufour-Lamartinie, M.D., appointed Chief Medical Officer

21 May 2021

Patent application filed for a method to enhance the efficacy of medical treatment using S1P lyase inhibitors.

16 December 2020

AC BioScience announces a License Agreement with Lexicon Pharmaceuticals Ltd. and closes third Seed Round for CHF 0.8 million.

23 September 2020

Patent application filed for immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases.

31 August 2020

Patent application filed for three kinase inhibitors and use thereof to mediate the loss of malignant character of tumor cells.

8 June 2020

AC BioScience presents at the International Cancer Cluster Showcase (ICCS), a satellite event to BIO 2020.

25 May 2020

AC BioScience raises CHF 1 million in second seed funding.

27 March 2020

Patent application filed for a combination of flavonoids and S1P lyase inhibitors for the treatment of lung inflammation.

15 March 2020

Patent application filed for RGD-peptide and use thereof for inhibiting RGD-binding integrins and for cancer treatment.

13 March 2020

Innosuisse approves research grant for a collaborative project with the University of Lausanne on a new therapy targeting pathogen-dependent immune subversion mechanisms for infectious diseases treatment.

7 January 2020

Collaboration Agreement signed with the Institut Gustave Roussy (IGR) for radiation therapy in combination with S1P metabolism modulators, and ACB1801 with anti PD-1 treatment, respectively.

26 August 2019

Cooperation Agreement signed with the Luxembourg Institute of Health (LIH) to determine the efficacy of combination approaches of ACB1801 with anti-PD-1 drugs.

21 August 2019

Patent application filed for various metabolites of S1P lyase inhibitors for the treatment of infectious diseases and cancer.

06 May 2019

AC BioScience presents at the Swiss Biotech Day 2019.

25 March 2019

Patent application filed for a Beta-carboline derivative (ACB1801) for the non-toxic and immunological treatment of cancer.

08 March 2019

AC BioScience raises CHF 1 million in seed funding.

November 2018

AC BioScience acquires a majority share in AC BioTech SAS in Paris.

29 May 2018

Collaborative Research Agreement signed with the University of British Columbia, Vancouver, on S1P lyase inhibitors.

26 April 2018

Innosuisse approves research grant for a collaborative project with the University of Geneva on tumor vascular normalizers (S1P).

April 2018

Collaborative Research Agreement signed with the Institut Curie, Paris; commencement of a pharmacological PDX study of NSCLC for CAP6.

24 August 2017

Conversion to a private limited stock company (Ltd.) with an increased capital of CHF 500,000; acquisition of a patent for a Peptide having the sequence SEQ.1 for use as a medicament, in particular for the treatment of cancer.

17 August 2017

Patent application filed for the enhancement of chemotherapy efficiency by Sphingosine-1-phosphate (S1P).

31 March 2017

AC BioScience established as a Limited Liability Company (LLC) at the EPFL Innovation Park.